Overcoming the innate immune response to small interfering RNA

Human Gene Therapy

Volumn 19, Issue 2, 2008, Pages 111-124

  Judge, Adam ^a   MacLachlan, Ian ^a  

^a Protiva Biotherapeutics   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERFERON; NUCLEIC ACID; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 4;

ANTIGEN RECOGNITION; DRUG EFFICACY; DRUG SAFETY; GENE SILENCING; HUMAN; IN VIVO STUDY; INNATE IMMUNITY; NONHUMAN; REVIEW; RNA SEQUENCE; RNA STRUCTURE;

ANIMALS; HUMANS; IMMUNITY, NATURAL; RNA, SMALL INTERFERING;

MAMMALIA;

EID: 39449097277     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2007.179     Document Type: Review

References (104)

1. ALEXOPOULOU, L., CZOPIK-HOLT, A., MEDZHITOV, R., and FLAVELL, R. (2001). Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413, 732-738.
2. ALLERSON, C.R., SIOUFI, N., JARRES, R., PRAKASH, T., MAIK, N., BERDEJA, A., WANDERS, L., GRIFFEY, R.H., SWAYZE, E.E., and BHAT, B. (2005). Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J. Med. Chem. 48, 901-904.
3. BALLAS, Z.K., RASMUSSEN, W.L., and KRIEG, A.M. (1996). Induction of NK activity in murine and human cells by CpG motifs in oligonucleotides and bacterial DNA. J. Immunol. 157, 1840-1845.
4. BEHLKE, M.A. (2006). Progress towards in vivo use of siRNAs. Mol. Ther. 13, 644-670.
5. BEKEREDJIAN-DING, I., WAGNER, M., HORNUNG, V., GIESE, T., SCHNURR, M., ENDRES, S., and HARTMANN, G. (2005). Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J. Immunol. 174, 4043-4050 [erratum in J. Immunol. 2005;174:5884].
6. BEKEREDJIAN-DING, I., ROTH, S.I., GILLES, S., GIESE, T., ABLASSER, A., HORNUNG, V., ENDRES, S., and HARTMANN, G. (2006). T cell-independent, TLR-induced IL-12p70 production in primary human monocytes. J. Immunol. 176, 7438-7446.
7. BIANCHI, M., MENG, C., and IVASHKIV, L.B. (2000). Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids. Proc. Natl. Acad. Sci. U.S.A. 97, 9573-9578.
8. BITKO, V., MUSIYENKO, A., SHULYAYEVA, O., and BARIK, S. (2005). Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 11, 50-55.
9. BOECKLER, C., DAUTEL, D., SCHELTE, P., FRISCH, B., WACHSMANN, D., KLEIN, J.P., and SCHUBER, F. (1999). Design of highly immunogenic liposomal constructs combining structurally independent B cell and T helper cell peptide epitopes. Eur. J. Immunol. 29, 2297-2308.
10. BRANNON-PEPPAS, L., GHOSN, B., ROY, K., and CORNETTA, K. (2007). Encapsulation of nucleic acids and opportunities for cancer treatment. Pharm. Res. 24, 618-627.
11. BRIDGE, A.J., PEBERNARD, S., DUCRAUX, A., NICOULAZ, A.L., and IGGO, R. (2003). Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. 34, 263-264.
12. CEKAITE, L., FURSET, G., HOVIG, E., and SIOUD, M. (2007). Gene expression analysis in blood cells in response to unmodified and 2′-modified siRNAs reveals TLR-dependent and independent effects. J. Mol. Biol. 365, 90-108.
13. CHIU, Y., and RANA, T. (2003). siRNA function in RNAi: A chemical modification analysis. RNA 9, 1034-1048.
14. CHRISTENSEN, S.R., SHUPE, J., NICKERSON, K., KASHGARIAN, M., FLAVELL, R.A., and SHLOMCHIK, M.J. (2006). Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25, 417-428.
15. CZAUDERNA, F., FECHTNER, M., DAMES, S., AYGUN, H., KLIPPEL, A., PRONK, G.J., GIESE, K., and KAUFMANN, J. (2003). Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31, 2705-2716.
16. DER, S.D., ZHOU, A., WILLIAMS, B.R., and SILVERMAN, R.H. (1998). Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc. Natl. Acad. Sci. U.S.A. 95, 15623-15628.
17. DIEBOLD, S.S., KAISHO, T., HEMMI, H., AKIRA, S., and REISE SOUSA, C. (2004). Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529-1531.
18. DIEBOLD, S.S., MASSACRIER, C., AKIRA, S., PATUREL, C., MOREL, Y., and REIS E SOUSA, C. (2006). Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur. J. Immunol. 36, 3256-3267.
19. ELBASHIR, S.M., HARBORTH, J., LENDECKEL, W., YALCIN, A., WEBER, K., and TSCHI, T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498.
20. ELMEN, J., THONBERG, H., LJUNGBERG, K., FRIEDEN, M., WESTERGAARD, M., XU, Y., WAHREN, B., LIANG, Z., ORUM, H., KOCH, T., and WAHLESTEDT, C. (2005). Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 33, 439-447.
21. FLYNN, M.A., CASEY, D.G., TODRYK, S.M., and MAHON, B.P. (2004). Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo. J. Inflamm. (Lond.) 1, 4.
22. FOLKMAN, J., and INGBER, D. (1992). Inhibition of angiogenesis. Semin. Cancer Biol. 3, 89-96.
23. FOSS, F.M. (2002). Immunologic mechanisms of antitumor activity. Semin. Oncol. 29, 5-11.
24. GE, Q., FILIP, L., BAI, A., NGUYEN, T., EISEN, H.N., and CHEN, J. (2004). Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. U.S.A. 101, 8676-8681.
25. GEISBERT, T.W., HENSLEY, L.E., KAGAN, E., YU, E.Z., GEISBERT, J.B., DADDARIO-DICAPRIO, K., FRITZ, E.A., JAHLING, P.B., MCCLINTOCK, K., PHELPS, J.S., LEE, A., JUDGE, A.D., JEFFS, L.B., and MACLACHLAN, I. (2006). Postexposure protection of guinea pigs against a lethal Ebola virus challenge by RNA interference. J. Infect. Dis. 193, 1650-1657.
26. GEISS, G., JIN, G., GUO, J., BUMGARNER, R., KATZE, M.G., and SEN, G.C. (2001). A comprehensive view of regulation of gene expression by double-stranded RNA-mediated cell signaling. J. Biol. Chem. 276, 30178-30182.
27. GORDEN, K.B., GORSKI, K.S., GIBSON, S.J., KEDL, R.M., KIEPER, W.C., QIU, X., TOMAI, M.A., ALKAN, S.S., and VASILAKOS, J.P. (2005). Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 174, 1259-1268.
28. HARDING, J., ENGBERS, C.M., NEWMAN, M.S., GOLDSTEIN, N.I., and ZALIPSKY, S. (1997). Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol) grafted immunoliposomes. Biochim. Biophys. Acta 1327, 181-192.
29. HART, O.M., ATHIE-MORALES, V., O'CONNOR, G.M., and GARDINER, C.M. (2005). TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-γ production. J. Immunol. 175, 1636-1642.
30. HEIDEL, J.D., YU, Z., LIU, J.Y., RELE, S.M., LIANG, Y., ZEIDAN, R.K., KORNBRUST, D.J., and DAVIS, M.E. (2007). Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. U.S.A. 104, 5715-5721.
31. HEIL, F., HEMMI, H., HOCHREIN, H., AMPENBERGER, F., KIRSCHNING, C., AKIRA, S., LIPFORD, G., WAGNER, H., and BAUER, S. (2004). Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303, 1526-1529.
32. HORNUNG, V., GUENTHNER-BILLER, M., BOURQUIN, C., ABLASSER, A., SCHLEE, M., UEMATSU, S., NORONHA, A., MANOHARAN, M., AKIRA, S., DE FOUGEROLLES, A., ENDRES, S., and HARTMANN, G. (2005). Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11, 263-270.
33. HORNUNG, V., ELLEGAST, J., KIM, S., BRZOZKA, K., JUNG, A., KATO, H., POECK, H., AKIRA, S., CONZELMANN, K.K., SCHLEE, M., ENDRES, S., and HARTMANN, G. (2006). 5′-Triphosphate RNA is the ligand for RIG-I. Science 314, 994-997.
34. JEGO, G., PALUCKA, A.K., BLANCK, J.-P., CHALOUNI, C., PASCUAL, V., and BANCHEREAU, J. (2003). Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19, 225-234.
35. JUDGE, A., SOOD, V., SHAW, J., FANG, D., MCCLINTOCK, K., and MACLACHLAN, I. (2005). Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23, 457-462.
36. JUDGE, A.D., BOLA, G., LEE, A.C.H., and MACLACHLAN, I. (2006a). Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13, 494-505.
37. JUDGE, A.D., MCCLINTOCK, K., SHAW, J.R., and MACLACHLAN, I. (2006b). Hypersensitivity and loss of disease site targeting caused by antibody responses to pegylated liposomes. Mol. Ther. 13, 328-337.
38. KARIKÓ, K., BHUYAN, P., CAPODICI, J., and WEISSMAN, D. (2004). Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through Toll-like receptor-3. J. Immunol. 172, 6545-6549.
39. KARIKÓ, K., BUCKSTEIN, M., NI, H., and WEISSMAN, D. (2005). Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165-175.
40. KATO, H., SATO, S., YONEYAMA, M., YAMAMOTO, M., UEMATSU, S., MATSUI, K., TSUJIMURA, T., TAKEDA, K., FUJITA, T., TAKEUCHI, O., and AKIRA, S. (2005). Cell type-specific involvement of RIG-I in antiviral response. Immunity 23, 19-28.
41. KATO, H., TAKEUCHI, O., SATO, S., YONEYAMA, M., YAMAMOTO, M., MATSUI, K., UEMATSU, S., JUNG, A., KAWAI, T., ISHII, K.J., YAMAGUCHI, O., OTSU, K., TSUJIMURA, T., KOH, C.S., REIS E SOUSA, C., MATSUURA, Y., FUJITA, T., and AKIRA, S. (2006). Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441, 101-105.
42. KAWAI, T., and AKIRA, S. (2006). Innate immune recognition of viral infection. Nat. Immunol. 7, 131-137.
43. KIM, D.-H., LONGO, M., HAN, Y., LUNDBERG, P., CANTIN, E., and ROSSI, J.J. (2004). Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat. Biotechnol. 22, 321-325.
44. KIM, D.H., BEHLKE, M.A., ROSE, S.D., CHANG, M.S., CHOI, S., and ROSSI, J.J. (2005). Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol. 23, 222-226.
45. KLINMAN, D.M. (2004). Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4, 249-258.
46. KLINMAN, D.M., YI, A.K., BEAUCAGE, S.L., CONOVER, J., and KRIEG, A.M. (1996). CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12 and interferon γ. Proc. Natl. Acad. Sci. U.S.A. 93, 2879-2833.
47. KRIEG, A.M. (2002). CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760.
48. KRIEG, A.M. (2006). Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5, 471-484.
49. LAU, C.M., BROUGHTON, C., TABOR, A.S., AKIRA, S., FLAVELL, R.A., MAMULA, M.J., CHRISTENSEN, S.R., SHLOMCHIK, M.J., VIGLIANTI, G.A., RIFKIN, I.R., and MARSHAK-ROTHSTEIN, A. (2005). RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202, 1171-1177.
50. LAYZER, J., MCCAFFREY, A., TANNER, A., HUANG, Z., KAY, M., and SULLENGER, B. (2004). In vivo activity of nuclease resistant siRNAs. RNA 10, 766-771.
51. LEUSCHNER, P.J., AMERES, S.L., KUENG, S., and MARTINEZ, J. (2006). Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBO Rep. 7, 314-320.
52. LI, B.J., TANG, Q., CHENG, D., QIN, C., XIE, F.Y., WEI, Q., XU, J., LIU, Y., ZHENG, B.J., WOODLE, M.C., ZHONG, N., and LU, P.Y. (2005). Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in rhesus macaque. Nat. Med. 11, 944-951.
53. LI, W., MAYER, L., and BALLY, M. (2002). Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J. Pharmacol. Exp. Ther. 300, 976-983.
54. LI, W.M., BALLY, M.B., and SCHUTZE-REDELMEIER, M.P. (2001). Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine 20, 148-157.
55. LIU, Y.-J. (2005). IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23, 275-306.
56. LYNN, M., ROSSIGNOL, D.P., WHEELER, J.L., KAO, R.J., PERDOMO, C.A., NOVECK, R., VARGAS, R., D'ANGELO, T., GOTZKOWSKY, S., and MCMAHON, F.G. (2003). Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J. Infect. Dis. 187, 631-639.
57. MANOHARAN, M. (2004). RNA interference and chemically modified small interfering RNAs. Curr. Opin. Chem. Biol. 8, 570-579.
58. MARQUES, J.T., DEVOSSE, T., WANG, D., ZAMANIAN-DARYOUSH, M., SERBINOWSKI, P., HARTMANN, R., FUJITA, T., BEHLKE, M.A., and WILLIAMS, B.R. (2006). A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat. Biotechnol. 24, 559-565.
59. MATRANGA, C., TOMARI, Y., SHIN, C., BARTEL, D.P., and ZAMORE, P.D. (2005). Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 123, 607-620.
60. MICHIE, H.R., MANOGUE, K.R., SPRIGGS, D.R., REVHAUG, A., ODWYER, S., DINARELLO, C.A., CERAMI, A., WOLFF, S.M., and WILMORE, D.W. (1988). Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 318, 1481-1486.
61. MOHTY, M., VIALLE-CASTELLANO, A., NUNES, J.A., ISNARDON, D., OLIVE, D., and GAUGLER, B. (2003). IFN-α skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities. J. Immunol. 171, 3385-3393.
62. MORRISSEY, D.V., BLANCHARD, K., SHAW, L., JENSEN, K., LOCKRIDGE, J.A., DICKINSON, B., MCSWIGGEN, J.A., VARGEESE, C., BOWMAN, K., SHAFFER, C.S., POLISKY, B.A., and ZINNEN, S. (2005a). Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus infection. Hepatology 41, 1349-1356.
63. MORRISSEY, D.V., LOCKRIDGE, J.A., SHAW, L., BLANCHARD, K., JENSEN, K., BREEN, W., HARTSOUGH, K., MACHEMER, L., RADKA, S., JADHAV, V., VAISH, N., ZINNEN, S., VARGEESE, C., BOWMAN, K., SHAFFER, C., JEFFS, L.B., JUDGE, A.D., MACLACHLAN, I., and POLISKY, B.A. (2005b). Potent and persistent in vivo anti-HBV activity of chemically modified siRNA's. Nat. Biotechnol. 23, 1002-1007.
64. MOYNAGH, P.N. (2003). Toll-like receptor signalling pathways as key targets for mediating the anti-inflammatory and immunosuppressive effects of glucocorticoids. J. Endocrinol. 179, 139-144.
65. NOVINA, C.D., MURRAY, M.F., DYKXHOORN, D.M., BERESFORD, P.J., RIESS, J., LEE, S.K., COLLMAN, R.G., LIEBERMAN, J., SHANKAR, P., and SHARP, P.A. (2002). siRNA-directed inhibition of HIV-1 infection. Nat. Med. 8, 681-686.
66. PALLISER, D., CHOWDHURY, D., WANG, Q.Y., LEE, S.J., BRONSON, R.T., KNIPE, D.M., and LIEBERMAN, J. (2006). An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439, 89-94.
67. PENG, S. (2005). Signaling in B cells via Toll-like receptors. Curr. Opin. Immunol. 17, 230-236.
68. PHILLIPS, N.C., and DAHMAN, J. (1995). Immunogenicity of immunoliposomes: Reactivity against species-specific IgG and liposomal phospholipids. Immunol. Lett. 45, 149-152.
69. PICHLMAIR, A., SCHULZ, O., TAN, C.P., NASLUND, T.I., LILJESTROM, P., WEBER, F., and REIS E SOUSA, C. (2006). RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314, 997-1001.
70. PISITKUN, P., DEANE, J.A., DIFILIPPANTONIO, M.J., TARASENKO, T., SATTERTHWAITE, A.B., and BOLLAND, S. (2006). Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312, 1669-1672.
71. PRAKASH, T., ALLERSON, C.R., DANDE, P., VICKERS, T., SIOUFI, N., JARRES, R., BAKER, B., SWAYZE, E.E., GRIFFEY, R.H., and BHAT, B. (2005). Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J. Med. Chem. 48, 4247-4253.
72. QUEZADA, A., HORNER, M.J., LOERA, D., FRENCH, M., PERICLE, F., JOHNSON, R., PERRARD, J., JENKINS, M., and COLEMAN, M. (2002). Safety toxicity study of plasmid-based IL-12 therapy in cynomolgus monkeys. J. Pharm. Pharmacol. 54, 241-248.
73. REICH, S.J., FOSNOT, J., KUROKI, A., TANG, W., YANG, X., MAGUIRE, A. BENNETT, J., and TOLENTINO, M. (2003). Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 9, 210-216.
74. ROBBINS, M., JUDGE, A., LIANG, L., MCCLINTOCK, K., YAWORSKI, E., and MACLACHLAN, I. (2007). 2′-O-Methyl-modified RNAs act as TLR7 antagonists. Mol. Ther. 15, 1663-1669.
75. ROSE, S.D., KIM, D.H., AMARZGUIOUI, M., HEIDEL, J.D., COLLINGWOOD, M.A., DAVIS, M.E., ROSSI, J.J., and BEHLKE, M.A. (2005). Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res. 33, 4140-4156.
76. SAMUEL, C.E. (2001). Antiviral actions of interferons. Clin. Microbiol. Rev. 14, 778-809.
77. SAUNDERS, L.R., and BARBER, G.N. (2003). The dsRNA binding protein family: Critical roles, diverse cellular functions. FASEB J. 17, 961-983.
78. SCHIFFELERS, R.M., ANSARI, A., XU, J., ZHOU, Q., TANG, Q., STORM, G., MOLEMA, G., LU, P.Y., SCARIA, P.V., and WOODLE, M.C. (2004). Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32, e149.
79. SCHLEE, M., HORNUNG, V., and HARTMANN, G. (2006). siRNA and isRNA: Two edges of one sword. Mol. Ther. 14, 463-470.
80. SCHLEE, M., BARCHET, W., HORNUNG, V., and HARTMANN, G. (2007). Beyond double-stranded RNA-type I IFN induction by 3pRNA and other viral nucleic acids. Curr. Top. Microbiol. Immunol. 316, 207-230.
81. SEMPLE, S.C., HARASYM, T.O., CLOW, K.A., ANSELL, S.M., KLIMUK, S.K., and HOPE, M.J. (2005). Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J. Pharmacol. Exp. Ther. 312, 1020-1026.
82. SHARARA, A.I., PERKINS, D.J., MISUKONIS, M.A., CHAN, S.U., DOMINITZ, J.A., and WEINBERG, J.B. (1997). Interferon (IFN)-α activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression: Possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-α in vivo. J. Exp. Med. 186, 1495-1502.
83. SIOUD, M. (2005). Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNA is sequence dependent and requires endosomal localization. J. Mol. Biol. 348, 1079-1090.
84. SLEDZ, C.A., HOLKO, M., DE VEER, M.J., SILVERMAN, R.H., and WILLIAMS, B.R. (2003). Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5, 834-839.
85. SMIRNOVA, I., POLTORAK, A., CHAN, E.K.L., MCBRIDE, C., and BEUTLER, B. (2000). Phylogenetic variation and polymorphism at the Toll-like receptor 4 locus (TLR4). Genome Biol. 1, 1-10.
86. SONG, E., LEE, S.K., DYKXHOORN, D.M., NOVINA, C., ZHANG, D., CRAWFORD, K., CERNY, J., SHARP, P.A., LIEBERMAN, J., MANJUNATH, N., and SHANKAR, P. (2003). Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J. Virol. 77, 7174-7181.
87. SONG, E., ZHU, P., LEE, S., CHOWDHURY, D., KUSSMAN, S., DYKXHOORN, D., FENG, Y., PALLISER, D., WEINER, D., SHANKAR, P., MARASCO, W., and LIEBERMAN, J. (2005). Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709-717.
88. SOUTSCHEK, J., AKINIC, A., BRAMLAGE, B., CHARISSE, K., CONSTEIN, R., DONOGHUE, M., ELBASHIR, S., GEIK, A., HADWIGER, P., HARBORTH, J., MATTHIAS, J., KESAVAN, V., LAVINE, G., PANDEY, R.K., RACIE, T., RAJEEV, K.G., RÖHL, I., TOUDJARSKA, I., WANG, G., WUSCHKO, S., BUMCROT, D., KOTELIANSKI, V., LIMMER, S., MANOHARAN, M., and VORNLOCHER, H.-P. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178.
89. STEVENSON, H.C., ABRAMS, P.G., SCHOENBERGER, C.S., SMALLEY, R.B., HERBERMAN, R.B., and FOON, K.A. (1985). A phase I evaluation of poly(I,C)-LC in cancer patients. J. Biol. Response Mod. 4, 650-655.
90. SUBRAMANIAN, S., TUS, K., LI, Q.Z., WANG, A., TIAN, X.H., ZHOU, J., LIANG, C., BARTOV, G., MCDANIEL, L.D., ZHOU, X.J., SCHULTZ, R.A., and WAKELAND, E.K. (2006). A TLR7 translocation accelerates systemic autoimmunity in murine lupus. Proc. Natl. Acad. Sci. U.S.A. 103, 9970-9975.
91. SUNTHARALINGAM, G., PERRY, M.R., WARD, S., BRETT, S.J., CASTELLO-CORTES, A., BRUNNER, M.D., and PANOSKALTSIS, N. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028.
92. TAKEDA, K., KAISHO, T., and AKIRA, S. (2003). Toll-like receptors. Annu. Rev. Immunol. 21, 335-376.
93. THOMAS, M., LU, J.J., GE, Q., ZHANG, C., CHEN, J., and KLIBANOV, A.M. (2005). Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc. Natl. Acad. Sci. U.S.A. 102, 5679-5684.
94. THOMSON, A., and LOTZE, M. (2003). The Cytokine Handbook. (Academic Press, San Diego, CA)
95. TOMPKINS, S.M., LO, C.Y., TUMPEY, T.M., and EPSTEIN, S.L. (2004). Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. U.S.A. 101, 8682-8686.
96. TSUBONIWA, N., MORISHITA, R., HIRANO, T., FUJIMOTO, J., FURUKAWA, S., KIKUMORI, M., OKUYAMA, A., and KANEDA, Y. (2001). Safety evaluation of hemagglutinating virus of Japan-artificial viral envelope liposomes in nonhuman primates. Hum. Gene Ther. 12, 469-487.
97. VOLLMER, J., TLUK, S., SCHMITZ, C., HAMM, S., JURK, M., FORSBACH, A., AKIRA, S., KELLY, K.M., REEVES, W.H., BAUER, S., and KRIEG, A.M. (2005). Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med. 202, 1575-1585.
98. VON MARSCHALL, Z., SCHOLZ, A., CRAMER, T., SCHAFER, G., SCHIRNER, M., OBERG, K., WIEDENMANN, B., HOCKER, M., and ROSEWICZ, S. (2003). Effects of interferon α on vascular endothelial growth factor gene transcription and tumor angiogenesis. J. Natl. Cancer Inst. 95, 437-448.
99. WEBB, M.S., TORTORA, N., CREMESE, M., KOZLOWSKA, H., BLAQUIERE, M., DEVINE, D.V., and KORNBRUST, D.J. (2001). Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys. Antisense Nucleic Acid Drug Dev. 11, 155-163.
100. WU, W.Z., SUN, H.C., SHEN, Y.F., CHEN, J., WANG, L., TANG, Z.Y., ILIAKIS, G., and LIU, K.D. (2005). Interferon α 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways. J. Cancer Res. Clin. Oncol. 131, 169-178.
101. YEO, S.J., YOON, J.G., and YI, A.K. (2003). Myeloid differentiation factor 88-dependent post-transcriptional regulation of cyclooxygenase-2 expression by CpG DNA: Tumor necrosis factor-α receptor-associated factor 6, a diverging point in the Toll-like receptor 9-signaling. J. Biol. Chem. 278, 40590-40600.
102. YI, A.K., CHACE, J.H., COWDERY, J.S., and KRIEG, A.M. (1996). IFN-γ promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligonucleotides. J. Immunol. 156, 558-564.
103. YONEYAMA, M., KIKUCHI, M., NATSUKAWA, T., SHINOBU, N., IMAIZUMI, T., MIYAGISHI, M., TAIRA, K., AKIRA, S., and FUJITA, T. (2004). The RNA helicase RIG-1 has an essential function in double-stranded RNA induced innate antiviral responses. Nat. Immunol. 5, 730-737.
104. ZIMMERMANN, T.S., LEE, A., AKINC, A., BRAMLAGE, B., BUMCROT, D., FEDORUK, M.N., HARBORTH, J., HEYES, J., JEFFS, L., MATTHIAS, J., JUDGE, A.D., LAM, K., MCCLINTOCK, K., NECHEV, L.V., PALMER, L., RACIE, T., RÖHL, I., SEIFFERT, S., SHANMUGAM, S., SOOD, V., SOUTSCHEK, J., TOUDJARSKA, I., WHEAT, A., YAWORSKI, E., ZEDALIS, W., KOTELIANSKY, V., MANOHARAN, M., VORNLOCHER, H.-P., and MACLACHLAN, I. (2006). RNAi-mediated gene silencing in non-human primates. Nature 441, 111-114.